ArticleActa pharmacologica Sinica2018
Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression.
Article in Acta pharmacologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 63 citations in OpenAlex.
- Trial
- Fluoxetine disrupts cholesterol metabolism in endothelial cells via SREBP2 activation.Translational psychiatry · 2026Article
- Role of central and peripheral serotonin in liver physiology and diseases.Theranostics · 2026Review
- Longitudinal metabolic profiling of women using selective serotonin reuptake inhibitors during pregnancy.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- The relationship of cardiometabolic index with bowel movement frequency: an NHANES-based cross-sectional analysis.Lipids in health and disease · 2025Article
- Fluoxetine promotes IL-10-dependent metabolic defenses to protect from sepsis-induced lethality.Science advances · 2025Article
- Abnormalities of lipid metabolism in the progression and treatment of depression.Frontiers in psychiatry · 2025Review
- Effects of selective serotonin reuptake inhibitors on endocrine system (Review).Biomedical reports · 2024Review
- Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role ofWorld journal of psychiatry · 2024Review
- Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers.Metabolites · 2024Review
- Upregulation of S100A8 in peripheral blood mononuclear cells from patients with depression treated with SSRIs: a pilot study.Proteome science · 2023Article
- Fluoxetine promotes immunometabolic defenses to mediate host-pathogen cooperation during sepsis.bioRxiv : the preprint server for biology · 2023Article
- Apolipoprotein D as a Potential Biomarker in Neuropsychiatric Disorders.International journal of molecular sciences · 2023Review
- Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics.Scientific reports · 2023Article
- Chronic salmon calcitonin exerts an antidepressant effectFrontiers in molecular neuroscience · 2023Article
- High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer.Frontiers in oncology · 2023Article
- Untargeted Metabolomics Reveals Antidepressant Effects in a Marine Photosynthetic Organism: The DiatomBiology · 2022Article
- New monoamine antidepressant, hypidone hydrochloride (YL-0919), enhances the excitability of medial prefrontal cortex in mice via a neural disinhibition mechanism.Acta pharmacologica Sinica · 2022Article
- Obesity II: Establishing causal links between chemical exposures and obesity.Biochemical pharmacology · 2022Review
- Effects of pharmacological treatment on metabolomic alterations in animal models of depression.Translational psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depressive disorders are frequently managed with long-term use of antidepressant medication. Fluoxetine (FLX) is the first selective serotonin reuptake inhibitor to be widely available for the treatment of depression. The present study focuses on the effects and mechanisms of the lipid metabolism abnormalities caused by FLX in patients and in a mouse model of depression. Depression severity was assessed by the Hamilton Depression Scale (HAMD). Triglyceride (TG), cholesterol (TC) and low-density lipoprotein (LDL) serum levels were assessed in 28 patients with depression, aged 31.2±3.3 years, treated with FLX (20 to 60 mg/day) for 8 weeks. Meanwhile, the serum levels of other lipid metabolism-related parameters, such as high-density lipoprotein (HDL), apolipoprotein A1 (APOA1) and apolipoprotein B (ApoB), were also determined. The infiuence of FLX on the hepatic lipid profile and hepatic gene expression of both lipogenic and lipolytic enzymes was evaluated in a mouse model of depression treated with FLX (10 mg·kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.